Previous 10 | Next 10 |
SAN DIEGO , April 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) by Janssen Pharmaceutical K.K. (Janssen) seeking approval of a new subcutaneous (S...
SAN DIEGO , April 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and well-being of our employees and stockholders, and to comply with the S...
Today, we will see why Halozyme Therapeutics ( HALO ) is an attractive pick in March 2020. Company overview Halozyme Therapeutics is a biopharmaceutical company that is leveraging its Enhanze drug delivery technology in collaboration with other pharmaceutical companies to develop and com...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...
SAN DIEGO , Feb. 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 11:20 a.m. ET / 8:20 a.m. PT in Boston . Dr. Helen Torley , president and chief executi...
Halozyme Therapeutics, Inc. (HALO) Q4 2019 Earnings Conference Call February 24, 2020 04:30 p.m. ET Company Representatives Helen Torley - President, Chief Executive Officer Al Kildani - Vice President of Investor Relations and Corporate Communications Conference Call Participan...
SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech, a member of the Roche Group, for the fixed-dose combination of pertuzu...
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q4 2019 Earnings Call Feb 24, 2020 , 4:30 p.m. ET Operator Continue reading
Halozyme Therapeutics (NASDAQ: HALO ) has dipped 1.5% postmarket after posting its Q4 report, where revenues and profits trailed expectations though the company reiterated strong guidance and upcoming sustained profitability. More news on: Halozyme Therapeutics, Inc., Healthcare stocks n...
Halozyme Therapeutics (NASDAQ: HALO ): Q4 GAAP EPS of -$0.24 misses by $0.06 . Revenue of $53.68M (-10.9% Y/Y) misses by $2.01M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...